secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001558370-23-002104
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix BioTherapeutics enters $20M at-the-market equity offering with H.C. Wainwright
--------------------------------------------------------------------------------

- ATM offering of up to $20M of common stock via H.C. Wainwright & Co. as sales agent.
- Proceeds for general corporate purposes, including working capital and clinical trials.
- Shares sold on NYSE American at prevailing market prices in 'at the market' transactions.
- Agreement supplements existing July 2021 ATM facility (amended May 2022).
- Offered under existing shelf registration statement (Form S-3, No. 333-264394).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/0001558370-23-002104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/plx-20230227x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer